Searched for
DEURUXOLITINIB APPROVAL
Sun Pharma shares in focus after $200 million settlement in US drug pricing caseShares of Sun Pharma will be in focus after the company said its subsidiaries, SPII and Taro, have agreed to pay $200 million to settle an ...- Sun Pharma’s baldness drug Leqselvi debuts in US market after patent dispute settledSun Pharmaceutical Industries has reached a settlement agreement with Incyte Corporation concerning Leqselvi, a drug for severe hair loss, ...
- Sun Pharma shares in focus following US launch of LEQSELVITM, settlement with Incyte CorporationSun Pharma shares: In a regulatory filing on Monday, Sun Pharma announced that it has reached a settlement and licensing agreement with Inc...
- I-Sec upgrades Sun Pharma to Buy, target price Rs 1,895ICICI Securities has upgraded Sun Pharmaceutical Industries to 'Buy' with a revised target price of Rs 1895. Sun Pharma, a leading company ...
- Sun Pharma's hair loss drug in the cross hairs in USLeqselvi is used for the treatment of alopecia areata, an autoimmune disease that leads to hair loss, and was approved by the US Food and D...
- Sun Pharma gets US FDA nod for its specialty drug against baldnessSun Pharma announced FDA approval of Leqselvi (deuruxolitinib) 8 mg tablets for severe alopecia areata, marking a major milestone after acq...
- Sun Pharma's drug to treat alopecia areata gets USFDA nodSun Pharmaceutical Industries Ltd announced that the USFDA has approved its drug LEQSELVI (deuruxolitinib) for treating adults with severe ...
- Time to buy pharma? 3 stocks Forum Parekh is betting onZydus Life's US business is going to report a good set of numbers. Also, in India, wellness products are doing good, Overall Zydus Life wil...
- Hot Stocks: Brokerages view on Avenue Supermarts, Bajaj Finance, ICICI Bank and Sun PharmaBrokerage firm HSBC maintained a buy rating on Sun Pharma, Citigroup recommended a buy rating on ICICI Bank, JPMorgan has an overweight rat...
- Sun Pharma's focus on specialty drugs pays offThe company's revenues grew 11% driven by strong growth posted by the India business and the global specialty sales in the US. A third of t...
- Sun Pharma Q2 Results: Cons profit rises 6% YoY to Rs 2,385 crore, beats estimatesOperating profit, calculated as earnings before interest, taxes, depreciation, and amortization (EBITDA), for the quarter, rose nearly 8% o...
- 3 stocks Nithya Balasubramanian is bullish on from pharma sectorWe have seen some players recall some products. We have seen some players file bankruptcies. So these will therefore create opportunities f...
- Sun Pharma Q4 Results: Firm clocks cons PAT of Rs 1,984 crore, declares Rs 4/share dividendThe company approved a final dividend of Rs 4 per equity share which will be subject to the approval of the shareholders. The total dividen...
- Stocks in news: HUL, RIL, L&T Tech, Sun Pharma, Jubilant Food, PVR, KIOCLRIL earnings are expected to be better than the Q2 numbers due to improvement in the mainstay energy business, coupled with steady performa...
- Sun Pharma to buy concert for $576 mConcert has pioneered the use of deuterium (a hydrogen isotope) in medicinal chemistry and has an extensive patent portfolio, including its...
Load More
